---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045724"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:24:00.734660+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vanda Q3 2024 revenue up 23% to $47.7M; guidance raised; net loss $5.3M

## Summary
- Q3 total net product sales $47.7M (+23% YoY); Fanapt $23.9M (+12%), HETLIOZ $17.9M (+2%), PONVORY $5.9M (-32% QoQ).
- Net loss $5.3M vs net income $0.1M in Q3 2023; diluted EPS loss $0.09.
- Cash $376.3M; guidance raised: FY revenue $190-210M, year-end cash $370-390M.
- Fanapt bipolar I launch: new patient starts +90% Q3 2024 vs Q3 2023; Fanapt LAI Phase III starts Q4 2024.
- Milsaperidone NDA for schizophrenia/bipolar I expected early 2025; tradipitant NDA for motion sickness in Q4 2024.

## SEC filing metadata
- accession: 0001628280-24-045724
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828024045724/0001628280-24-045724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828024045724/vnda-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045724
- JSON: https://secwatch.observer/filing/0001628280-24-045724.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.